Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login
Market Place

Formulation Strategies for Poorly Soluble Molecules services provided by Quotient Sciences

Quotient Sciences
Formulation Strategies for Poorly Soluble Molecules
Full Screen View

Uploaded: 2018

Quotient And Vasa Begin Human Trials Of VS-041 For Novel Heart Failure Therapy

11 Sep 2024

// PRESS RELEASE

Quotient Sciences Wins 2024 CRO Leadership Awards

05 Jun 2024

// PRESS RELEASE

Quotient Sciences Announces New Facility Leadership in Philadelphia, PA

05 Jun 2024

// PRESS RELEASE

DATA COMPILATION
#PharmaFlow

Quotient rm 250x250

Contact Supplier

CPhI Worldwide, Milan

Booth #7A90

Book a meeting now

envelop Contact Supplier

Xls

CATEGORY PAGE

Quotient Sciences

VISIT THE VIRTUAL BOOTH, Contact Details

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

EVENTS

Webinars & Exhibitions

Webinars & Exhibitions

PRESENTATION(s)

Corporate Presentation, First Subjects Dosing with VS-041 a Novel Heart Failure Treatment, 14C Human ADME Program for HTD1801, Oxilio & Quotient Announce Regulatory Approval for OXL001, Expansion of Facilities for Translational Pharmaceutics® Programs, Ensysce Biosciences & Quotient Announce a Partnership, Human ADME Studies, Bioanalytical Services, Translational Pharmaceutics®, Formulation Strategies for Poorly Soluble Molecules, Global Formulation Development & Manufacturing Capabilities, Commercial Manufacturing, Clinical Trial Manufacturing, Global Clinical Trial Supplies, GMP Certificate 2019, Financial Impact of Translational Pharmaceutics®, High Potency Handling, Project Management at Quotient Sciences, Pediatrics Services, Formulation Development, Clinical Pharmacology

Corporate Presentation
First Subjects Dosing with VS-041 a Novel Heart Failure Treatment
14C Human ADME Program for HTD1801
Oxilio & Quotient Announce Regulatory Approval for OXL001
Expansion of Facilities for Translational Pharmaceutics® Programs
Ensysce Biosciences & Quotient Announce a Partnership
Human ADME Studies
Bioanalytical Services
Translational Pharmaceutics®
Formulation Strategies for Poorly Soluble Molecules
Global Formulation Development & Manufacturing Capabilities
Commercial Manufacturing
Clinical Trial Manufacturing
Global Clinical Trial Supplies
GMP Certificate 2019
Financial Impact of Translational Pharmaceutics®
High Potency Handling
Project Management at Quotient Sciences
Pediatrics Services
Formulation Development
Clinical Pharmacology

VIDEO(s)

Corporate Video, Bioanalytical Services, Candidate Molecule Selection, CDMO Solutions for Orphan & Rare Diseases, Early Development, Late Development, Orphan Drug Programs, What is Bioanalysis? (BioA), Our Manifesto, Miami Clinical Pharmacology Facility

Corporate Video
Bioanalytical Services
Candidate Molecule Selection
CDMO Solutions for Orphan & Rare Diseases
Early Development
Late Development
Orphan Drug Programs
What is Bioanalysis? (BioA)
Our Manifesto
Miami Clinical Pharmacology Facility

DIGITAL CONTENT

3 INTERVIEW #SpeakPharma, 31 CORPORATE CONTENT #SupplierSpotlight, 1 DATA COMPILATION #PharmaFlow, 136 NEWS #PharmaBuzz

3 INTERVIEW #SpeakPharma
31 CORPORATE CONTENT #SupplierSpotlight
1 DATA COMPILATION #PharmaFlow
136 NEWS #PharmaBuzz

DEVELOPMENTS

21 Drugs in Development

21 Drugs in Development

SERVICES

Analytical, Clinical Trials, API Manufacturing, Drug Product Manufacturing, API & Drug Product Development, Packaging

Analytical
- 1 BioAnalytical Services
- 1 Analytical Method Development
Clinical Trials
API Manufacturing
Drug Product Manufacturing
API & Drug Product Development
Packaging
- 5 Clinical Services

KEY SERVICES

Pharmacy Compounding Services, Pharmacy Compounding & Formulation Services, Formulation Development of Capsules, Development of Nasal Dosage Forms, CDMO for Suspensions, Pediatric Formulation Development

Pharmacy Compounding Services
Pharmacy Compounding & Formulation Services
Formulation Development of Capsules
Development of Nasal Dosage Forms
CDMO for Suspensions
Pediatric Formulation Development

INSPECTIONS & REGISTRATIONS

6 FDA, 7 EDQM, 1 GDUFA

6 FDA
7 EDQM
1 GDUFA

PI72998

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
LOOKING FOR A SUPPLIER?